05.02.2010 • Product

New Solventless, Fast-cure Adhesive Improves Productivity and Lowers Laminating Costs

The Adhesives and Functional Polymers business unit of The Dow Chemical Company has announced the availability of its new Mor-Free L75-173/C-145 solvent-free, 100% solids, polyurethane adhesive system for flexible packaging.

The two-component product is formulated as a lower-cost alternative to adhesives currently on the market for laminating and general-to-medium performance packaging applications. The company is advising converters seeking to lower production costs for packaging laminations that this fast-curing Mor-Free adhesive can be applied at room temperature, and such laminates can generally be further processed in as little as six hours. Chemical curing typically requires up to five days at ambient temperatures. New Mor-Free L75-173/C-145 may be run at speeds as high as 1500 feet per minute while maintaining excellent appearance on a wide variety of substrates. It can be used for laminating all polyolefin films, including LDPE to LDPE, OPP to OPP, and OPP to LDPE, as well as nylon, aluminum, polyester, and other packaging substrates. The films may be unprinted or reverse printed with the appropriate laminating grade inks. A long pot life is also a feature of this adhesive.

 

Company

The Dow Chemical Company

100 Larkin Center
48674 Midland
US

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read